Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 2 | 2022 | 215 | 1.270 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 2 | 2022 | 84 | 0.880 |
Why?
|
| End Stage Liver Disease | 1 | 2021 | 33 | 0.710 |
Why?
|
| Hydronephrosis | 1 | 2020 | 8 | 0.680 |
Why?
|
| Kidney Pelvis | 1 | 2020 | 12 | 0.670 |
Why?
|
| Ureteral Obstruction | 1 | 2020 | 21 | 0.670 |
Why?
|
| Cysts | 1 | 2020 | 41 | 0.660 |
Why?
|
| Ureter | 1 | 2020 | 34 | 0.660 |
Why?
|
| Colorectal Neoplasms | 1 | 2021 | 280 | 0.580 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 339 | 0.570 |
Why?
|
| Gout Suppressants | 1 | 2015 | 22 | 0.470 |
Why?
|
| Gout | 1 | 2015 | 48 | 0.460 |
Why?
|
| Postoperative Complications | 1 | 2021 | 1284 | 0.440 |
Why?
|
| Medication Adherence | 1 | 2015 | 196 | 0.420 |
Why?
|
| Transplant Recipients | 2 | 2022 | 33 | 0.380 |
Why?
|
| Neoplasms | 1 | 2022 | 1350 | 0.370 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2021 | 13 | 0.330 |
Why?
|
| Carcinoma, Hepatocellular | 2 | 2021 | 178 | 0.280 |
Why?
|
| Incidence | 2 | 2022 | 1367 | 0.280 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 295 | 0.270 |
Why?
|
| Presenilin-1 | 2 | 2012 | 61 | 0.200 |
Why?
|
| Risk Factors | 2 | 2022 | 5303 | 0.180 |
Why?
|
| Cholangiocarcinoma | 1 | 2021 | 30 | 0.180 |
Why?
|
| SEER Program | 1 | 2021 | 74 | 0.180 |
Why?
|
| Bile Duct Neoplasms | 1 | 2021 | 46 | 0.180 |
Why?
|
| Retroperitoneal Space | 1 | 2020 | 22 | 0.170 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2019 | 4 | 0.170 |
Why?
|
| bcl-X Protein | 1 | 2019 | 20 | 0.160 |
Why?
|
| Nephrectomy | 1 | 2020 | 80 | 0.160 |
Why?
|
| Drainage | 1 | 2020 | 154 | 0.160 |
Why?
|
| Early Detection of Cancer | 1 | 2021 | 315 | 0.140 |
Why?
|
| Male | 5 | 2022 | 29487 | 0.140 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2017 | 8 | 0.140 |
Why?
|
| Age Factors | 1 | 2021 | 1554 | 0.130 |
Why?
|
| Population Surveillance | 1 | 2018 | 203 | 0.130 |
Why?
|
| Humans | 9 | 2022 | 62682 | 0.120 |
Why?
|
| Alzheimer Disease | 2 | 2012 | 718 | 0.120 |
Why?
|
| Adult | 3 | 2021 | 16629 | 0.120 |
Why?
|
| Apoptosis | 1 | 2019 | 1066 | 0.110 |
Why?
|
| Risk Assessment | 1 | 2021 | 2040 | 0.110 |
Why?
|
| Amyloid beta-Peptides | 2 | 2012 | 297 | 0.110 |
Why?
|
| Disease Management | 1 | 2015 | 234 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 1589 | 0.100 |
Why?
|
| Amyloid beta-Protein Precursor | 1 | 2012 | 86 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2015 | 748 | 0.090 |
Why?
|
| Retrospective Studies | 2 | 2021 | 6533 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2019 | 1508 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2015 | 435 | 0.080 |
Why?
|
| Neurons | 2 | 2012 | 909 | 0.080 |
Why?
|
| Middle Aged | 3 | 2021 | 17365 | 0.080 |
Why?
|
| Aging | 1 | 2012 | 740 | 0.070 |
Why?
|
| Female | 4 | 2021 | 32495 | 0.060 |
Why?
|
| Aged | 1 | 2021 | 14254 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2012 | 890 | 0.040 |
Why?
|
| Mice, Transgenic | 2 | 2012 | 1271 | 0.040 |
Why?
|
| Cellular Senescence | 1 | 2019 | 110 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2019 | 215 | 0.040 |
Why?
|
| Blood Viscosity | 1 | 2017 | 4 | 0.040 |
Why?
|
| Plasmapheresis | 1 | 2017 | 18 | 0.030 |
Why?
|
| Muscle Weakness | 1 | 2017 | 33 | 0.030 |
Why?
|
| Mice | 3 | 2019 | 10804 | 0.030 |
Why?
|
| Rituximab | 1 | 2017 | 83 | 0.030 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2017 | 46 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 576 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 644 | 0.030 |
Why?
|
| Accidental Falls | 1 | 2017 | 128 | 0.030 |
Why?
|
| Liver | 1 | 2019 | 845 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 964 | 0.030 |
Why?
|
| Animals | 3 | 2019 | 20584 | 0.030 |
Why?
|
| Frontotemporal Lobar Degeneration | 1 | 2012 | 21 | 0.030 |
Why?
|
| Plaque, Amyloid | 1 | 2012 | 40 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2012 | 126 | 0.020 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 60 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2012 | 610 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2012 | 400 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 294 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2012 | 411 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2012 | 774 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2012 | 2154 | 0.020 |
Why?
|
| United States | 1 | 2018 | 7721 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2012 | 5403 | 0.010 |
Why?
|